Abel DeLaRosa, PhD 


John Thomas, CPA

Audit Chair

Rick Keefer


Skip Pridgen, MD Founder


Greg Duncan


Chief Executive

Richard Burch



Rich Whitely,



Greg Duncan is the Chief Executive Officer and a Member of the Board of Directors of Virios Therapeutics. Previously, Mr. Duncan  was President and Chief Executive Officer of Celtaxsys, Inc., a privately held biotech company focused on developing anti-inflammatory medicines for rare disease where he scaled the required capital to build out the organizational capability to advance both pre- clinical and clinical development candidates.  Prior to Celtaxsys, he served as an Executive Committee member at Belgium based UCB, a specialty pharma entity developing and commercializing medicines for immunologic and central nervous system disorders. Before joining UCB, Mr. Duncan, while at Pfizer he held several executive U.S. and international appointments, including President of Pfizer’s $2B Latin America Operations and SVP of Marketing. His operational teams had accountability for the launches of many pharmaceutical brands including Lipitor, Zoloft, Viagra, Celebrex, Aricept, Lyrica, Cimzia, Zithromax (ZPack), Diflucan, Sutent, Rebif and Vimpat. Mr. Duncan has served as director for Biotie Therapeutics, the American Psychiatric Foundation, Bio International Organization (BIO), Southeast BIO (SEBIO and the Georgia Bio industry association groups. Greg holds a master’s degree in business administration from Emory University in Atlanta, GA, and a bachelor’s degree in economics from the State University of New York in Albany, NY.

Richard Burch is the President of Virios Therapeutics.  Prior to joining Virios, Mr. Burch spent 30 years at Pfizer starting as a sales rep and working his way up to Senior Vice President overseeing numerous divisions with more than 6,500 employees. He was accountable for $11.5 billion in revenue and had responsibilities in launching or managing over
20 pharmaceutical products, including blockbuster brands such as Celebrex, Lyrica, Aricept, Zoloft, Rebif, Zithromax and Lipitor.  Following his tenure at Pfizer, Mr. Burch was named Vice President and General Manager for UCB, Inc., overseeing all operations for the US CNS Business Unit including P&L management and responsibility for pipeline and in-line portfolio of CNS products. Mr. Burch currently serves on the University of Alabama Business School Board and is a member of the University of Alabama President’s Cabinet and on the Executive Committee for the DCH Health System Foundation Board. Mr. Burch received a bachelor’s degree in Marketing from the University of Alabama and certification from the Finance and Accounting Department of Columbia University’s Graduate School of Business.

  • CorMatrix Cardiovascular DemeRx, Inc.

  • MiMedx Group, Inc. 

  • DARA BioSciences

  • GMP Companies 

  • MRI Interventions

  • EnterMed, Inc. 

  • Medicis Pharm Corp. 

  • CytRx Corp

  • Gilead's Board of Director

  • Distinguished Professor Loeb Scholar Chair in Pediatrics, and Professor of Microbiology,Medicine and Neurosurgery, UAB

  • Co-Founder & Co-Director, Alabama Drug Discovery Alliance

  • 380 Publications

  • Obama H1N1 Task Force

  • Remdesivir was Originally Developed by Dr Whitley’s team at UAB

  • Company Founder

  • Board- certified surgeon practicing with Tuscaloosa Surgical Associates, P.C.

  • Spent nearly 20 years searching for effective treatments in IBS, FM, and CFS/ME

  • Served as a physician and surgeon in the United States Navy

  • 30-year Pharma industry veteran with broad-based experience in leading commercial operations.

  • Seven-time winner of Pharma Voice’s top 100 leaders in healthcare

  • Executive roles at Pharmacia, Pfizer, Wyeth, Biovail and Publicis Health

  • CEO, Director, co-founder of Antios Therapeutics

  • Chief Scientific Officer of Drug Innovation Ventures at Emory

  • Led acquisition of Pharmasset by Gilead Sciences (NASDAQ: GILD) for $11.5 billion in 2012

  • Led Drug Development Programs for the Treatment of HIV, Hepatitis B and C, including Sofosbuvir